Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial (Q38996447)

8 September 2017

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial (English)

1 reference

8 September 2017

phase II clinical trial

0 references

0 references

1 reference

1 reference

Sil Kordes

1

1 reference

8 September 2017

Michael N Pollak

2

1 reference

8 September 2017

Aeilko H Zwinderman

3

1 reference

8 September 2017

Ron A Mathôt

4

1 reference

8 September 2017

Mariëtte J Weterman

5

1 reference

8 September 2017

Aart Beeker

6

1 reference

8 September 2017

Cornelis J Punt

7

1 reference

8 September 2017

Dick J Richel

8

1 reference

8 September 2017

Johanna W Wilmink

9

1 reference

8 September 2017

8 June 2015

1 reference

Lancet Oncology Commission

8 September 2017

1 reference

8 September 2017

16

1 reference

8 September 2017

839-847

1 reference

8 September 2017

7

1 reference

Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment

8 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Investigating metformin for cancer prevention and treatment: the end of the beginning

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Metformin use is associated with better survival of diabetic patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Metformin and the risk of cancer: time-related biases in observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Metformin directly acts on mitochondria to alter cellular bioenergetics.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Insulin and insulin-like growth factor signalling in neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Targeting mitochondria metabolism for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Carbon source and myc expression influence the antiproliferative actions of metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Serine deprivation enhances antineoplastic activity of biguanides.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Metformin and erlotinib synergize to inhibit basal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Pancreatic cancer treatment and research: an international expert panel discussion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Metformin and pancreatic cancer: a clue requiring investigation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Phenformin as prophylaxis and therapy in breast cancer xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

Essential role for oxidative phosphorylation in cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900027-3

7 January 2021

10.1016/S1470-2045(15)00027-3

Identifiers

DOI

1 reference

8 September 2017

1 reference